Evoke Pharma, Inc.
EVOK
$5.49
$0.0761.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 21.81% | -6.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.81% | -6.90% | |||
| Cost of Revenue | 303.13% | -64.89% | |||
| Gross Profit | 17.97% | -4.75% | |||
| SG&A Expenses | 19.49% | -1.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.20% | -2.67% | |||
| Operating Income | -19.76% | -9.05% | |||
| Income Before Tax | -20.27% | -9.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.27% | -9.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.27% | -9.51% | |||
| EBIT | -19.76% | -9.05% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -20.06% | -49.33% | |||
| Normalized Basic EPS | -20.07% | -49.32% | |||
| EPS Diluted | -20.06% | -49.33% | |||
| Normalized Diluted EPS | -20.07% | -49.32% | |||
| Average Basic Shares Outstanding | 0.18% | -26.66% | |||
| Average Diluted Shares Outstanding | 0.18% | -26.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||